Blog

SEC EDGAR, FINRA BrokerCheck, USASpending.gov, USPTO, PACER, and ClinicalTrials.gov are all free and open to the public. Each one tells a different part of the story. Here is what each database contains, which companies it matters most for, and what you will find there that never makes it into a press release.

OpenAI burns $14B per year, will not break even until 2029 or 2030, and its financing structure makes traditional valuation nearly impossible. Here are the questions every investor should ask before buying into the AI IPO wave.

Raise cash, find a SPAC, announce bitcoin holdings, watch the stock pop. VanEck warned the real test is surviving a downturn. Here is what separates a real treasury strategy from a narrative trade.

SpaceX is profitable, Starlink is approaching 5 million subscribers, and the launch business has no real competitor at scale. But a $1.5 trillion valuation still demands the same scrutiny you would apply to any stock.

NuScale, X-energy, Kairos, Oklo, and others promise cheap clean baseload power. But most are pre-revenue with decade-long timelines, and the most advanced project was cancelled when costs nearly doubled. Here is how to separate genuine progress from a compelling pitch deck.

Robotics ETFs promise exposure to next-gen automation. But many hold large positions in decades-old industrial companies like Fanuc, Keyence, and ABB. Here is what you are actually buying versus what the marketing suggests.

Every rare earth SPAC pitch deck mentions the EV boom and China risk. But most of the 2021-2022 critical minerals SPACs are trading at pennies or have delisted. Here is what separated the survivors from the failures: permits, capex realism, and management track record.

MP Materials, Lynas, and Energy Fuels are positioned as the Western answer to Chinese rare earth dominance. But mining is one thing, refining is another. Most Western miners still ship ore to China for processing. Here is what to look for in the SEC filings.